BARACLUDE(R) (entecavir) Demonstrated Greater Antiviral Efficacy Compared To Adefovir In New Study Of Chronic Hepatitis B Patients With CirrhosisBristol-Myers Squibb (NYSE: BMY) today announced 48-week data from an ongoing study (ETV-048) of chronicdemonstrated greater viral suppression compared to adefovir. The new BARACLUDE data were presented today at the 60th Annual Meeting of the American Association...
